tiprankstipranks
OmniAb initiated with an Outperform at Cowen
The Fly

OmniAb initiated with an Outperform at Cowen

Cowen initiated coverage of OmniAb with an Outperform rating and $10 price target. OmniAb has a pure-play antibody drug discovery platform that is focused and "highly scalable," the analyst tells investors in a research note. The scale of the discovery engine is reflected in the "high-quality partner list and robust program pipeline with attractive downstream economics," says the firm. It has conviction the company can capitalize on its downstream potential.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on OABI:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles